Optical imaging agent developer Edinburgh Molecular Imaging (EM Imaging) has begun a pivotal phase IIb clinical trial to assess the use of its EMI-137 molecular optical imaging agent in patients with a high suspicion of colorectal cancer.
The study will be conducted by the Center for Human Drug Research (CHDR), a clinical research organization based in Leiden, Netherlands. The organization will collaborate closely on the trial with the Leiden University Medical Center and the University Medical Center of Groningen, according to EM Imaging.
